Multiple Sclerosis: Update Bulletin #1 [February 2018]
This edition presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market. Topics covered include: Roche’s announcement that Ocrevus (ocrelizumab) has been approved by the European Commission as a treatment for RRMS and PPMS; Mylan announcing the UK launch of Brabio (glatiramer acetate injection; 40 mg/ml), a generic version of Copaxone; as well as Merck KGaA’s potential FDA resubmission for Mavenclad (cladribine tablets) as a therapy for relapsing forms of MS.
How is Ocrevus expected to be prescribed once launched?
Which agents are anticipated to lose market share as a result of Ocrevus’ launch?
How do KOLs view Brabio and how successful is it likely to be?
How do KOLs view Mavenclad, and how successful has the European launch been?
How is Mavenclad currently prescribed?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook